Followers | 65 |
Posts | 7222 |
Boards Moderated | 0 |
Alias Born | 03/06/2016 |
Thursday, April 13, 2017 1:39:12 PM
What the FDA should do is not to consider INSPIRE successful UNTIL EACH APPROVED SITE completes at least one procedure.
No point approving something with only a handful of hospitals every attempting the procedure.
The second arm should be an independent study that's runs concurrent with INSPIRE. Two results and two approvals. To say this will not increase the timeline is genuinely misleading. Mark is the only person who believes this. I bet he doesn't even truly believe it.
This company had so much potential. Too bad there were so many missteps.
Even with 4 more conversions we will be lucky to see $4
Good luck to anybody still invested here.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM